WALTHAM, Mass. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ:NURO) today announced that Shai N. Gozani M.D., Ph.D., President and CEO of NeuroMetrix, is scheduled to speak at the upcoming LD Micro Annual Main Event at the Luxe Sunset Bel Air Hotel in Los Angeles, CA. Dr.
WALTHAM, Mass. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,130,810 titled “Transcutaneous electrical nerve stimulation with user gesture detector and electrode-skin contact detector,
WALTHAM, Mass. , Nov. 15, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), announced today that it had executed a distribution agreement with Fukuda Denshi Co. Ltd. for DPNCheck ® , the Company’s rapid, point-of-care test for diabetic peripheral neuropathy (DPN).
WALTHAM, Mass. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,112,040 titled “Transcutaneous electrical nerve stimulation using novel unbalanced biphasic waveform and novel electrode
WALTHAM, Mass. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), reported that DPNCheck ® , its rapid, point-of-care test for diabetic peripheral neuropathy (DPN), will be featured in several scientific sessions at the 33 rd Japan Society of Diabetic Complications Meeting in
$3.8M GSK Milestone; Improved Operating Performance WALTHAM, Mass. , Oct. 17, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2018 . The Company develops and markets novel therapies for chronic health
WALTHAM, Mass. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (NASDAQ:NURO) announced today that it plans to issue its 2018 third quarter financial results before the opening of the market on Wednesday, October 17, 2018. The Company will host a conference call at 8:00 a.m., Eastern
WALTHAM, Mass. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today reported publication of a clinical study of Quell ® wearable pain relief in the Journal of Pain and Relief. The paper is titled “Real-World Evidence for the Widespread Effects of Fixed-Site High Frequency
WALTHAM, Mass. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), today announced that it will showcase its latest product innovation, Quell ® 2.0 Wearable Pain Relief Technology™, during a workshop at DTxDM East, and will discuss using real world, patient generated data to
WALTHAM, Mass. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), reported that its President and CEO, Dr. Shai N. Gozani , yesterday participated in a discussion of the opioid crisis and the Company’s Quell ® Wearable Pain Relief Technology™ on Mornings with Maria on the Fox
